A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19

Jung Ho Kim, Sungmin Kym, Shin-Woo Kim, Dae Won Park, Ki Tae Kwon, Jun-Won Seo, Seungjin Yu, Goeun Choi, Sanoj Rejinold N, Jin-Ho Choy (), Geun-woo Jin and Jun Yong Choi ()
Additional contact information
Jung Ho Kim: Yonsei University College of Medicine
Sungmin Kym: Chungnam National University School of Medicine
Shin-Woo Kim: Kyungpook National University
Dae Won Park: Ansan-si
Ki Tae Kwon: Kyungpook National University
Jun-Won Seo: Dong-gu
Seungjin Yu: Dankook University
Goeun Choi: Dankook University
Sanoj Rejinold N: Dankook University
Jin-Ho Choy: Dankook University
Geun-woo Jin: LTD
Jun Yong Choi: Yonsei University College of Medicine

Nature Communications, 2025, vol. 16, issue 1, 1-9

Abstract: Abstract Effective and reliable treatments for SARS-CoV-2 infections are a key part of global COVID-19 management. Based on vitro studies, niclosamide has been considered as a potential drug candidate for SARS-CoV-2, but its clinical development has been limited due to poor solubility and bioavailability. Here we report results from a randomized, double-blind, placebo-controlled clinical trial involving 300 patients (Clinical Trial Registration Number: KCT0007307) that assessed the efficacy and safety of the niclosamide nanohybrid CP-COV03 at two different doses. Oral CP-COV03 was well tolerated, with no serious adverse events reported in any treatment group. The primary endpoints demonstrated that CP-COV03 significantly alleviated all 12 FDA-recommended COVID-19 symptoms, with symptom improvement sustained for more than 48 h. Additionally, CP-COV03 reduced SARS-CoV-2 viral load by 56.7% within 16 h of the initial dose compared to baseline. Secondary endpoints, including time to sustained symptom resolution, time to return to usual health, and reduction in hospitalization risk, also showed favorable results in the CP-COV03 group compared to placebo. These findings indicate that CP-COV03 is a safe and effective therapeutic option for the treatment of mild to moderate COVID-19 and represents a promising advancement in the repurposing of niclosamide through nanohybrid engineering.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-62423-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-62423-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-62423-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().